- In adults and adolescents with uncontrolled asthma receiving daily inhaled corticosteroid (ICS), adding leukotriene receptor antagonist (LTRA) reduced exacerbation and improved lung function and control compared with same dose ICS alone.
- No evidence of superiority vs increased dose ICS.
Why this matters
- LTRA+ICS is recommended by the Global Initiative for Asthma for patients aged ≥12 y with persistent uncontrolled asthma.
- 2004 Cochrane review found no benefit of adding LTRA vs same/increased ICS dose.
- Since that time, more evidence has been published.
- The current review determined available evidence does not support the use of LTRA as an ICS sparing agent.
- Cochrane review identified 37 studies (6128 patients) in search on CENTRAL, MEDLINE, EMBASE, PsycINFO, and 4 other databases till August 2016.
- Funding: National Institute for Health Research.
- LTRA+ICS vs same dose ICS al...